Lloyd Anderson, MD
Neurology · Tucson, AZNPI 1467432237
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $115 of the $128 with a category attached, or 89.9%. 4 manufacturers reported payments, led by Eisai Inc. at 49.6% of the total. 2023 is the largest year on record at $81, 3.9 times the $21 reported in 2020. That places this record below the midpoint for neurology clinicians in AZ, where the typical reported total is $1,232.
Across 8 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$64
- MDD US Operations, LLC$52
- Almatica Pharma LLC$12
- Travere Therapeutics, Inc.$1
Across 94 payments — averaging $4477.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biohaven Pharmaceuticals, Inc.$187K
- UCB SA$116K
- AbbVie$87K
- Biohaven Pharmaceutical Holding Company Ltd.$22K
- Eli Lilly$5K
- Pfizer$4K
What the payments were for
- Food & beverage$11590%
- Education$1310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 3 | $64 |
| MDD US Operations, LLC | 3 | $52 |
| Almatica Pharma LLC | 1 | $12 |
| Travere Therapeutics, Inc. | 1 | $1 |
How this compares
$128 in reported general payments places this provider in the 20th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 51 | $149,790 |
| NuplazidPimavanserin Tartrate | 14 | $135,954 |
| Dimethyl Fumarate | 18 | $64,636 |
| NeuproRotigotine | 18 | $32,534 |
| Teriflunomide | 11 | $32,206 |
| Dalfampridine ErDalfampridine | 22 | $24,297 |
| Emgality PenGalcanezumab-Gnlm | 24 | $22,348 |
| Aimovig AutoinjectorErenumab-Aooe | 28 | $20,915 |
| Nurtec OdtRimegepant Sulfate | 18 | $20,893 |
| RivastigmineRivastigmine Tartrate | 162 | $10,700 |
| Levetiracetam | 249 | $8,299 |
| Gabapentin | 428 | $7,462 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 338 | $7,226 |
| Rivastigmine | 40 | $6,288 |
| Lamotrigine | 258 | $5,488 |
Paid to pharmacies, not to this prescriber.
Other neurology in Tucson
- Francisco ValdiviaTucson$137K
- Cynthia ReedTucson$111K
- Yeeck SimTucson$38K
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Nida LaurinScottsdale$969K
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.